DOI 10.15252/emmm.201404792 |Published online 30.12.2014
EMBO Molecular Medicine(2014)emmm.201404792
Second Edition
AIDS Medicines and diagnostics services
July 2015
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
Annex to Selection and use of Ebola in vitro diagnostic assays
Zika and dengue viruses remain significant public health threats. These viruses share the same Aedes (Stegomyia) mosquito vectors and geographic distributions but infections cannot be readily distinguished clinically and need to be differentiated from each other, and from other circulating arboviral... and non-arboviral pathogens, using laboratory tests. This document provides guidance on current testing strategies for Zika and dengue virus infections with updates to the previous interim guidance for laboratory testing for ZIKV, addressing pregnant and non-pregnant patients respectively, and incorporates current guidance for dengue virus diagnostic testing. The choice of laboratory assays and interpretation of test results require careful consideration of epidemiology, patient history, and limitations of existing diagnostic tests.
This interim guidance is for use by staff of laboratories testing for Zika and dengue virus infections and for clinical practitioners and public health professionals providing clinical management or surveillance.
more
O recente aumento dos casos de microcefalia e outras patologias neurológicas potencialmente associadas à infecção pelo vírus Zika provocou um aumento da procura de testes laboratoriais para detectar a infecção. Os grupos prioritários para os testes de diagnóstico devem ser
indivíduos sin...tomáticos e mulheres grávidas assintomáticas com possível exposição ao vírus Zika. O presente documento fornece orientações sobre as actuais estratégias de testes da infecção pelo vírus Zika. Este documento será revisto e actualizado à medida que surgirem novas informações.
more
This document aims to present an algorithm for deciding whom to test and provide guidance on the laboratory tests for Zika virus infection diagnosis in order to support clinical diagnostic and case reporting through surveillance among EU Member States. The algorithm is not intended for clinical man...agement of patients with suspected Zika virus infection.
The information is provisional and subject to revision when new information becomes available.
more
El reciente aumento de los casos de microcefalia y de otros trastornos neurológicos posiblemente asociados a la infección por el virus de Zika ha provocado un aumento de la demanda de pruebas de laboratorio para detectar dicha infección. Los grupos prioritarios para la realización de pruebas di...agnósticas son los pacientes sintomáticos y las embarazadas asintomáticas posiblemente expuestas al virus.
En el presente documento, que será revisado y actualizado cuando se disponga de más información, se ofrece orientación sobre las actuales estrategias relativas a la realización de pruebas para la infección por el virus de Zika.
more
A manual for health care providers.
This manual provides expert guidance on the laboratory techniques and procedures used in the diagnosis of Buruli ulcer, a disease caused by Mycobacterium ulcerans. Aimed at laboratory technicians and scientists working on this disease, the manual details the exac...t procedures to follow when performing a range of diagnostic tests. Recommended procedures, intended for use throughout the health system, are presented at levels appropriate for peripheral, district and central services and in accordance with the varying resources, skills and equipment typically found in countries where Buruli ulcer is endemic.
more
Thirty-three years after its discovery, the Human Immunodeficiency Virus (HIV), responsible for the AIDS pandemic, remains a major public health problem despite advanced researches providing better diagnostic and therapeutic tools. The virus targets especially CD4+ T cells, leading to deficiency of ...the immune system and altering therefore defense against infections and cancer cells. Antiretroviral
more
Qualitative assay for use on the cobas®6800/8800 Systems. For in vitro diagnostic use
Given the current situation of the COVID-19 pandemic, countries are advised to continue adopting the TB diagnostic algorithms recommended by PAHO / WHO.
Despite the differences in the modes of transmission of TB and COVID-19, certain personal protection measures are relevant for both diseases. Rout...ine measures to protect yourself from TB should continue along with additional precautions to protect workers from COVID-19.
more
The speed of developing diagnostics for SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has been quite remarkable. Diagnostics have focused on nucleic acid amplification testing (NAAT) to identify infected individuals in acute-phase disease for timely implementation of mitiga...tion strategies and case management. More and more immunodiagnostics, mostly rapid diagnostic tests, are being made available as an alternative to NAATs. This type of test can be used out-of-laboratory conditions at large scale.
more
8 January 2021
Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. Continued genome sequencing supports the monitoring of the disease’s spread and evolution of the virus. Accelerated integration of genome sequencing int...o the practices of the global health community is required if we want to be better prepared for the future threats. This document provides guidance for laboratories on maximizing the impact of SARS-CoV-2 sequencing now and other emerging pathogens in the future.
more
medios de diagnóstico, tratamientos y grado de preparación respecto a las vacunas y otros productos sanitarios: módulo de las evaluaciones armonizadas de la capacidad de los centros de salud en el contexto de la pandemia de COVID-19, 7 de julio de 2021
O Ministério da Saúde atualiza o Diagnosticar para Cuidar com o PLANO NACIONAL DE EXPANSÃO DA TESTAGEM PARA COVID-19 (PNE-Teste) que tem a finalidade de expandir o diagnóstico da covid-19 por meio do teste rápido de antígeno (TR-AG), para uso em indivíduos sintomáticos e assintomáticos, par...a monitorar a situação epidemiológica e direcionar os esforços desta Pasta ministerial na contenção da pandemia no território nacional.
more
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...ing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
more
Se estima que unos 10 millones de personas contrajeron tuberculosis (TB) en el 2019 y que a unos 3 millones de ellas no se les diagnosticó ni se les notificó la enfermedad. Con el propósito de poner fin a la epidemia mundial de la tuberculosis para el 2030, sigue siendo necesario ampliar la capac...idad para analizar un gran número de muestras.
more
Objetivos:
- Reforzar la importancia del informe anatomopatológico en el manejo del cáncer
de mama, como elemento fundamental para la toma de decisiones.
- Estandarizar los procedimientos de las técnicas anatomopatológicas a nivel
nacional.
- Establecer los factores pronósticos morfoló...gicos, inmunohistoquímicos y
moleculares validados actualmente.
- Establecer un protocolo de informe anatomopatológico completo, reproducible y
estandarizado, orientado a contribuir en el manejo clínico y en la elaboración de
bases de datos.
more
A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to
Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d...ata on the clinical presentation of T.b. rhodesiense HAT is available. From 2006-2009 we conducted the first clinical trial program (I MPAMEL III) in T.b. rhodesiense endemic areas of
Tanzania and Uganda in accordance with international standards (ICH-GCP). The primary and secondary outcome measures were safety and efficacy of an abridged melarsoprol schedule for treatment of second stage disease. Based on diagnostic findings and clinical examinations at baseline we describe the clinical presentation of T.b. rhodesiense HAT in second stage patients from two distinct geographical settings in East Africa.
more